Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene.
Breast cancer patients presenting with symptomatic brain metastases have poor prognosis, and current chemotherapeutic agents are largely ineffective. In this study, we evaluated the hypomethylating agent azacitidine (AZA) for its potential as a novel therapeutic in preclinical models of brain metastasis of breast cancer. We used the parental triple-negative breast cancer MDA-MB-231 (231) cells and their brain colonizing counterpart (231Br) to ascertain phenotypic differences in response to AZA. We observed that 231Br cells have higher metastatic potential compared to 231 cells. With regard to therapeutic value, the AZA IC
Published In/Presented At
Butler, C., Sprowls, S., Szalai, G., Arsiwala, T., Saralkar, P., Straight, B., Hatcher, S., Tyree, E., Yost, M., Kohler, W. J., Wolff, B., Putnam, E., Lockman, P., & Liu, T. (2020). Hypomethylating Agent Azacitidine Is Effective in Treating Brain Metastasis Triple-Negative Breast Cancer Through Regulation of DNA Methylation of Keratin 18 Gene. Translational oncology, 13(6), 100775. https://doi.org/10.1016/j.tranon.2020.100775
Medicine and Health Sciences
Department of Medicine, Department of Medicine Fellows and Residents, Fellows and Residents